Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > 10 patients early 2021 for 25 for Breakthrough Designation

<< Previous

Bullboard Posts

Next >>

Comment by DJDawgon Mar 19, 2021 2:00pm

231 Views

Post# 32839127

RE:RE:RE:RE:RE:RE:10 patients early 2021 for 25 for Breakthrough Designation

Thanks for the link, I had read them. It was just a bit confusing:
14 patients as primary
5 maint (what does that mean). Treated properly and done?
5 removed (why?)

Remaining 9.
At 90 day, 3 were complete responders, 3 non responders, 2 partial, 1 TBD

At 180, 4 complete (is that the first 3 plus 1 from which category in 90 day
At 180, non-responder is now just 1, so does that mean 2 converted to responder? Sounds great if that is what it means.
At 180, 2 are now TBD...how does TBD increase from 90 to 180 days?

I really don't mean to ask dumb questions. I really have read as much as can find.

<< Previous

Bullboard Posts

Next >>

The investment impact of the U.S. 25% tariff on Canadian imports